Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

US National Institutes of Health (NIH) / National Cancer Institute (NCI) grant open #PAR-25-444

Response due Sep 25, 2028 · 00:00 UTC

Summary

The National Institutes of Health (NIH), specifically the National Cancer Institute (NCI), is offering Cancer Center Support Grants (CCSGs) under program announcement PAR-25-444. These grants are intended to support NCI-designated Cancer Centers through the P30 mechanism, with clinical trials optional. The opportunity is open for a multi-year window from November 2025 through September 2028, allowing eligible cancer centers to apply for institutional support funding.

What they want

Technical requirements

Applicant institution must hold or be seeking NCI Cancer Center designation
Clinical trials component is optional under P30 mechanism

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

Eligibility is inherently restricted to NCI-designated Cancer Centers, which is a small, pre-defined pool of institutions — effectively limiting competition to a narrow set of known recipients.
Multi-year open window (2025–2028) with a rolling submission structure may favor established incumbents already holding NCI designation.

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Cancer Center Support Grants (CCSGs) for N…

Due Sep 25

Onboard ↗